|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
1999-3-4
|
|
pubmed:abstractText |
The improved lung deposition of hydrofluoroalkane-134a beclomethasone dipropionate (HFA-BDP) extrafine aerosol compared with chlorofluorocarbon beclomethasone dipropionate (CFC-BDP) suggests that lower doses of HFA-BDP may be required to provide equivalent asthma control. The present study was undertaken to test this hypothesis.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
0012-3692
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
115
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
343-51
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:10027430-Adult,
pubmed-meshheading:10027430-Aerosols,
pubmed-meshheading:10027430-Anti-Asthmatic Agents,
pubmed-meshheading:10027430-Asthma,
pubmed-meshheading:10027430-Beclomethasone,
pubmed-meshheading:10027430-Chlorofluorocarbons,
pubmed-meshheading:10027430-Double-Blind Method,
pubmed-meshheading:10027430-Drug Combinations,
pubmed-meshheading:10027430-Female,
pubmed-meshheading:10027430-Glucocorticoids,
pubmed-meshheading:10027430-Humans,
pubmed-meshheading:10027430-Hydrocarbons, Fluorinated,
pubmed-meshheading:10027430-Male,
pubmed-meshheading:10027430-Peak Expiratory Flow Rate,
pubmed-meshheading:10027430-Treatment Outcome
|
|
pubmed:year |
1999
|
|
pubmed:articleTitle |
Hydrofluoroalkane-134a beclomethasone dipropionate, 400 microg, is as effective as chlorofluorocarbon beclomethasone dipropionate, 800 microg, for the treatment of moderate asthma.
|
|
pubmed:affiliation |
Dallas Allergy and Asthma Center, TX, USA.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
